# A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Source: https://onco.cc/trials/nct07258979/  
OnCo record `nct07258979` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL201, Toripalimab, Cisplatin in nasopharyngeal carcinoma, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. is a phase 1/2 interventional study registered as NCT07258979 by MediLink Therapeutics (Suzhou) Co., Ltd., with 202 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-02. Interventions recorded: YL201, Toripalimab, Cisplatin. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07258979
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 202

## Sources

- ClinicalTrials.gov NCT07258979: https://clinicaltrials.gov/study/NCT07258979

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Toripalimab](https://onco.cc/drugs/toripalimab/), [YL201](https://onco.cc/drugs/yl201/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07258979.json